122 related articles for article (PubMed ID: 37913974)
1. Combined inhibition of pyruvate dehydrogenase kinase 1 and hexokinase 2 induces apoptsis in non-small cell lung cancer cell models.
Guo Y; Lu X; Zhou Y; Chen WH; Tam KY
Exp Cell Res; 2023 Dec; 433(2):113830. PubMed ID: 37913974
[TBL] [Abstract][Full Text] [Related]
2. Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models.
Guo Y; Zhou Y; Wu P; Ran M; Xu N; Shan W; Sha O; Tam KY
Chem Biol Interact; 2023 Jun; 378():110467. PubMed ID: 37004952
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.
Zhou Y; Guo Y; Ran M; Shan W; Granchi C; Giovannetti E; Minutolo F; Peters GJ; Tam KY
Cancer Lett; 2023 Nov; 577():216425. PubMed ID: 37805163
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2.
Zhang K; Zhang M; Jiang H; Liu F; Liu H; Li Y
Biomed Pharmacother; 2018 Sep; 105():545-552. PubMed ID: 29886375
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
7. Ilimaquinone Induces the Apoptotic Cell Death of Cancer Cells by Reducing Pyruvate Dehydrogenase Kinase 1 Activity.
Kwak CH; Jin L; Han JH; Han CW; Kim E; Cho M; Chung TW; Bae SJ; Jang SB; Ha KT
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825675
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
[TBL] [Abstract][Full Text] [Related]
9. Andrographolide suppresses aerobic glycolysis and induces apoptotic cell death by inhibiting pyruvate dehydrogenase kinase 1 expression.
Yang ES; Do Y; Cheon SY; Kim B; Ling J; Cho MK; Kim T; Bae SJ; Ha KT
Oncol Rep; 2023 Apr; 49(4):. PubMed ID: 36825595
[TBL] [Abstract][Full Text] [Related]
10. PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism.
Lin H; Han H; Yang M; Wen Z; Chen Q; Ma Y; Wang X; Wang C; Yin T; Wang X; Lu G; Chen H; Qi J; Yang Y
Eur J Med Chem; 2023 Mar; 249():115166. PubMed ID: 36731272
[TBL] [Abstract][Full Text] [Related]
11. Hexokinases II-mediated glycolysis governs susceptibility to crizotinib in ALK-positive non-small cell lung cancer.
Lin C; Chen H; Han R; Li L; Lu C; Hao S; Wang Y; He Y
Thorac Cancer; 2021 Dec; 12(23):3184-3193. PubMed ID: 34729938
[TBL] [Abstract][Full Text] [Related]
12. Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer.
De Rosa V; Iommelli F; Monti M; Fonti R; Votta G; Stoppelli MP; Del Vecchio S
Clin Cancer Res; 2015 Nov; 21(22):5110-20. PubMed ID: 26216352
[TBL] [Abstract][Full Text] [Related]
13. Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis.
Li W; Gao F; Ma X; Wang R; Dong X; Wang W
Oncotarget; 2017 May; 8(20):32586-32599. PubMed ID: 28427230
[TBL] [Abstract][Full Text] [Related]
14. A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.
Ma Y; Yu C; Mohamed EM; Shao H; Wang L; Sundaresan G; Zweit J; Idowu M; Fang X
Oncogene; 2016 Nov; 35(47):6132-6142. PubMed ID: 27132509
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines.
Yang Z; Tam KY
Eur J Pharmacol; 2016 Oct; 789():458-467. PubMed ID: 27514773
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
17. Repression of Hexokinases II-Mediated Glycolysis Contributes to Piperlongumine-Induced Tumor Suppression in Non-Small Cell Lung Cancer Cells.
Zhou L; Li M; Yu X; Gao F; Li W
Int J Biol Sci; 2019; 15(4):826-837. PubMed ID: 30906213
[TBL] [Abstract][Full Text] [Related]
18. PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.
Pai S; Yadav VK; Kuo KT; Pikatan NW; Lin CS; Chien MH; Lee WH; Hsiao M; Chiu SC; Yeh CT; Tsai JT
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768921
[No Abstract] [Full Text] [Related]
19. Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway.
Li W; Ma X; Li N; Liu H; Dong Q; Zhang J; Yang C; Liu Y; Liang Q; Zhang S; Xu C; Song W; Tan S; Rong P; Wang W
Exp Cell Res; 2016 Dec; 349(2):320-327. PubMed ID: 27829129
[TBL] [Abstract][Full Text] [Related]
20. Targeting glucose metabolism to develop anticancer treatments and therapeutic patents.
Zhou Y; Guo Y; Tam KY
Expert Opin Ther Pat; 2022 Apr; 32(4):441-453. PubMed ID: 35001793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
